Brainstorm Cell Therapeutics Inc - Asset Resilience Ratio
Brainstorm Cell Therapeutics Inc (BCLI) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how Brainstorm Cell Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Brainstorm Cell Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Brainstorm Cell Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Brainstorm Cell Therapeutics Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Brainstorm Cell Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Brainstorm Cell Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Brainstorm Cell Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Brainstorm Cell Therapeutics Inc (2011–2023)
The table below shows the annual Asset Resilience Ratio data for Brainstorm Cell Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $4.21 Million | -- |
| 2022-12-31 | 26.16% | $2.21 Million | $8.45 Million | +15.10pp |
| 2021-12-31 | 11.06% | $3.24 Million | $29.28 Million | +3.05pp |
| 2020-12-31 | 8.01% | $4.11 Million | $51.26 Million | +7.51pp |
| 2019-12-31 | 0.51% | $33.00K | $6.53 Million | -54.02pp |
| 2018-12-31 | 54.52% | $6.12 Million | $11.23 Million | +8.36pp |
| 2017-12-31 | 46.16% | $5.27 Million | $11.42 Million | -41.55pp |
| 2016-12-31 | 87.71% | $9.44 Million | $10.77 Million | -3.20pp |
| 2015-12-31 | 90.91% | $15.53 Million | $17.08 Million | +47.62pp |
| 2014-12-31 | 43.29% | $4.29 Million | $9.91 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $4.73 Million | -- |
| 2012-12-31 | 52.15% | $2.77 Million | $5.31 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $2.74 Million | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modul… Read more